Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Conditions
Interventions
Oral repotrectinib (TPX-0005)
Locations
165
United States
Local Institution - 2129
Duarte, California, United States
Local Institution - 2120
Glendale, California, United States
Local Institution - 2136
La Jolla, California, United States
Local Institution - 2114
La Jolla, California, United States
Local Institution - 2121
Long Beach, California, United States
Local Institution - 1001
Orange, California, United States
Start Date
March 7, 2017
Primary Completion Date
February 29, 2028
Completion Date
February 29, 2028
Last Updated
April 3, 2026
NCT07403721
NCT06248411
NCT06716138
NCT06307795
NCT05753722
NCT05581004
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286Clinical.Trials@bms.comFirst line of the email MUST contain NCT # and Site #.
CONTACT
Lead Sponsor
Turning Point Therapeutics, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions